Redx Pharma plc New Grant of Options and Director/PDMR Dealing (8531D)
July 01 2021 - 6:08AM
UK Regulatory
TIDMREDX
RNS Number : 8531D
Redx Pharma plc
01 July 2021
Redx Pharma plc
("Redx" or "the Company")
New Grant of Options and Director/PDMR Dealing
Alderley Park, 1 July 2021 Redx Pharma (AIM:REDX), the drug
discovery and development company focused on cancer and fibrosis,
announces that new options have been awarded under the Redx
Directors Share Option Scheme (the "Scheme"), as adopted on 30 June
2021.
On 1 July 2021 the Board granted options to Peter Presland
(Interim Chairman), Dr. Bernhard Kirschbaum (Non-Executive
Director) and Sarah Gordon Wild (Non-Executive Director), all of
whom are classed as PDMRs, as set out further below. The options
were granted at an exercise price of 61.5p per ordinary share,
being the closing price on 30 June 2021.
Name Position Number of Vesting Date Total Options
Options Held Following
Granted the Grant
Interim Chairman
Peter Presland and Non-Executive
(Director/PDMR) Director 66,666 1 July 2022
66,667 1 July 2023
66,667 1 July 2024 200,000
Bernhard Kirschbaum Non-Executive
(Director/PDMR) Director 66,666 1 July 2022
66,667 1 July 2023
66,667 1 July 2024 200,000
Sarah Gordon Non-Executive
Wild (Director/PDMR) Director 66,666 1 July 2022
66,667 1 July 2023
66,667 1 July 2024 200,000
In addition, options over a further 700,000 Ordinary Shares of
1p each were granted on 1 July 2021 to certain new staff of the
Company under the Redx All Employees Share Option Scheme. These
options will also be granted at an exercise price of 61.5p, and are
not subject to performance conditions.
Following the grants referred to above, the Company will have
granted options over a total of 34,648,764 Ordinary Shares
representing 12.65 per cent. of the share capital in issue. The
number of options that may be awarded under the Scheme, the All
Employees Share Option Scheme and all prior share incentive plans,
remains limited such that the aggregate number of Ordinary Shares
of 1p each under option will be less than 15 per cent. of the total
issued share capital of the Company.
Further information in respect of the options granted to
directors is set out in the tables below in accordance with the
Market Abuse Regulation.
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name Peter Presland
------------------------------- ------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------------
a) Position/status Director
------------------------------- ------------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------- ------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Redx Pharma Plc
------------------------------- ------------------------------------------
b) LEI 213800HMS4EBXO589Y37
------------------------------- ------------------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
---------------------------------------------------------------------------
a) Description of the financial Options over Ordinary Shares of 1p
instrument each
------------------------------- ------------------------------------------
b) Identification code ISIN: GB00BSNB6S51
------------------------------- ------------------------------------------
c) Nature of the transactions Grant of options under the Redx Directors
Share Option Scheme
------------------------------- ------------------------------------------
d) Price(s) and volume(s) Exercise price: 61.5p pence per ordinary
share
Volume: 200,000 ordinary shares
------------------------------- ------------------------------------------
e) Aggregated information As for d) above
- Aggregated volume
- Price
------------------------------- ------------------------------------------
f) Date of the transactions 1 July 2021
------------------------------- ------------------------------------------
f) Place of the transactions Off-market
------------------------------- ------------------------------------------
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name Bernhard Kirschbaum
------------------------------- ------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------------
a) Position/status Director
------------------------------- ------------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------- ------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Redx Pharma Plc
------------------------------- ------------------------------------------
b) LEI 213800HMS4EBXO589Y37
------------------------------- ------------------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
---------------------------------------------------------------------------
a) Description of the financial Options over Ordinary Shares of 1p
instrument each
------------------------------- ------------------------------------------
b) Identification code ISIN: GB00BSNB6S51
------------------------------- ------------------------------------------
c) Nature of the transactions Grant of options under the Redx Directors
Share Option Scheme
------------------------------- ------------------------------------------
d) Price(s) and volume(s) Exercise price: 61.5p pence per ordinary
share
Volume: 200,000 ordinary shares
------------------------------- ------------------------------------------
e) Aggregated information As for d) above
- Aggregated volume
- Price
------------------------------- ------------------------------------------
f) Date of the transactions 1 July 2021
------------------------------- ------------------------------------------
f) Place of the transactions Off-market
------------------------------- ------------------------------------------
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name Sarah Gordon Wild
------------------------------- ------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------------
a) Position/status Director
------------------------------- ------------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------- ------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Redx Pharma Plc
------------------------------- ------------------------------------------
b) LEI 213800HMS4EBXO589Y37
------------------------------- ------------------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
---------------------------------------------------------------------------
a) Description of the financial Options over Ordinary Shares of 1p
instrument each
------------------------------- ------------------------------------------
b) Identification code ISIN: GB00BSNB6S51
------------------------------- ------------------------------------------
c) Nature of the transactions Grant of options under the Redx Directors
Share Option Scheme
------------------------------- ------------------------------------------
d) Price(s) and volume(s) Exercise price: 61.5p pence per ordinary
share
Volume: 200,000 ordinary shares
------------------------------- ------------------------------------------
e) Aggregated information As for d) above
- Aggregated volume
- Price
------------------------------- ------------------------------------------
f) Date of the transactions 1 July 2021
------------------------------- ------------------------------------------
f) Place of the transactions Off-market
------------------------------- ------------------------------------------
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
918
Peter Presland, Interim Chairman
Lisa Anson, Chief Executive
SPARK Advisory Partners (Nominated Adviser) T: +44 203 368
3550
Matt Davis/Adam Dawes
WG Partners LLP (Financial adviser & Joint Broker) T: +44 20 3705
9330
Claes Spång/David Wilson
Panmure Gordon (UK) Ltd (Joint Broker) T: +44 20 7886
2500
Rupert Dearden/Freddy Crossley/Emma Earl
FTI Consulting T: +44 20 3727
1000
Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and
development of novel targeted medicines for the treatment of cancer
and fibrotic diseases, aiming initially to progress them to
clinical proof of concept, before evaluating options for further
development and potential value creation. Redx's lead oncology
asset, RXC004, is currently in a Phase 1 study in patients with
advanced malignancies and Redx intends to report the Phase 1
clinical study results at a scientific meeting, as well as initiate
multiple Phase 2 studies in H2 2021. The Company's selective ROCK2
inhibitor, RXC007, is in development for idiopathic pulmonary
fibrosis and commenced a Phase 1 clinical study in June 2021 for
which results are expected in 2022.
The Company has a strong track record of discovering new drug
candidates through its core capability of converting medicinal
chemistry insights into differentiated and commercially attractive
drug candidates, and has previously completed preclinical asset
transactions with Loxo Oncology (now Eli Lilly), AstraZeneca and
Jazz Pharmaceuticals.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUARRRABUBRAR
(END) Dow Jones Newswires
July 01, 2021 06:08 ET (10:08 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Nov 2023 to Nov 2024
